The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis

Fan Yang, Qixia Wang, Zhaoyue Wang, Qi Miao, Xiao Xiao, Ruqi Tang, Xiaoyu Chen, Zhaolian Bian, Haiyan Zhang, Yue Yang, Li Sheng, Jingyuan Fang, Dekai Qiu, Edward L. Krawitt, M. Eric Gershwin, Xiong Ma

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Although a variant of primary biliary cirrhosis (PBC) characterized by features of autoimmune hepatitis (AIH) has been recognized for many years, few studies with ample numbers of patients have focused on its natural history. This study aimed to clarify the natural history, prognosis, and response to therapy in a cohort of patients with PBC with AIH features. We retrospectively analyzed 277 PBC patients without AIH features and 46 PBC patients with AIH features seen between September 2004 and April 2014. The 5-year adverse outcome-free survival of PBC patients with AIH features was 58 % compared to 81 % in PBC patients without AIH features. Multivariate analysis in the patients with AIH features indicated that total bilirubin ≥2.70× the upper limit of normal predicted a poor prognosis (p = 0.008, relative risk 8.39, 95% confidence interval (CI) 1.73, 40.73). Combination therapy with ursodeoxycholic acid (UDCA) and immunosuppression provided better short-term responses in PBC patients with AIH features, defined by multiple criteria. Higher aspartate aminotransferase (AST) level at accession suggested better prognosis for PBC patients with AIH features while worse prognosis for PBC patients without AIH features. PBC patients with AIH features differ from those without AIH features in terms of natural history, prognostic indicators, and response to therapy.

Original languageEnglish (US)
Pages (from-to)114-123
Number of pages10
JournalClinical Reviews in Allergy and Immunology
Volume50
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Autoimmune Hepatitis
Biliary Liver Cirrhosis
Natural History
Ursodeoxycholic Acid
Aspartate Aminotransferases
Bilirubin
Immunosuppression
Therapeutics
Multivariate Analysis

Keywords

  • Autoantibodies
  • Autoimmune hepatitis
  • Autoimmunity
  • Cholestasis
  • Overlap syndrome
  • Primary biliary cirrhosis

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis. / Yang, Fan; Wang, Qixia; Wang, Zhaoyue; Miao, Qi; Xiao, Xiao; Tang, Ruqi; Chen, Xiaoyu; Bian, Zhaolian; Zhang, Haiyan; Yang, Yue; Sheng, Li; Fang, Jingyuan; Qiu, Dekai; Krawitt, Edward L.; Gershwin, M. Eric; Ma, Xiong.

In: Clinical Reviews in Allergy and Immunology, Vol. 50, No. 1, 01.02.2016, p. 114-123.

Research output: Contribution to journalArticle

Yang, F, Wang, Q, Wang, Z, Miao, Q, Xiao, X, Tang, R, Chen, X, Bian, Z, Zhang, H, Yang, Y, Sheng, L, Fang, J, Qiu, D, Krawitt, EL, Gershwin, ME & Ma, X 2016, 'The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis', Clinical Reviews in Allergy and Immunology, vol. 50, no. 1, pp. 114-123. https://doi.org/10.1007/s12016-015-8516-5
Yang, Fan ; Wang, Qixia ; Wang, Zhaoyue ; Miao, Qi ; Xiao, Xiao ; Tang, Ruqi ; Chen, Xiaoyu ; Bian, Zhaolian ; Zhang, Haiyan ; Yang, Yue ; Sheng, Li ; Fang, Jingyuan ; Qiu, Dekai ; Krawitt, Edward L. ; Gershwin, M. Eric ; Ma, Xiong. / The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis. In: Clinical Reviews in Allergy and Immunology. 2016 ; Vol. 50, No. 1. pp. 114-123.
@article{3c078c5609ed4a16b88643c73126751b,
title = "The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis",
abstract = "Although a variant of primary biliary cirrhosis (PBC) characterized by features of autoimmune hepatitis (AIH) has been recognized for many years, few studies with ample numbers of patients have focused on its natural history. This study aimed to clarify the natural history, prognosis, and response to therapy in a cohort of patients with PBC with AIH features. We retrospectively analyzed 277 PBC patients without AIH features and 46 PBC patients with AIH features seen between September 2004 and April 2014. The 5-year adverse outcome-free survival of PBC patients with AIH features was 58 {\%} compared to 81 {\%} in PBC patients without AIH features. Multivariate analysis in the patients with AIH features indicated that total bilirubin ≥2.70× the upper limit of normal predicted a poor prognosis (p = 0.008, relative risk 8.39, 95{\%} confidence interval (CI) 1.73, 40.73). Combination therapy with ursodeoxycholic acid (UDCA) and immunosuppression provided better short-term responses in PBC patients with AIH features, defined by multiple criteria. Higher aspartate aminotransferase (AST) level at accession suggested better prognosis for PBC patients with AIH features while worse prognosis for PBC patients without AIH features. PBC patients with AIH features differ from those without AIH features in terms of natural history, prognostic indicators, and response to therapy.",
keywords = "Autoantibodies, Autoimmune hepatitis, Autoimmunity, Cholestasis, Overlap syndrome, Primary biliary cirrhosis",
author = "Fan Yang and Qixia Wang and Zhaoyue Wang and Qi Miao and Xiao Xiao and Ruqi Tang and Xiaoyu Chen and Zhaolian Bian and Haiyan Zhang and Yue Yang and Li Sheng and Jingyuan Fang and Dekai Qiu and Krawitt, {Edward L.} and Gershwin, {M. Eric} and Xiong Ma",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s12016-015-8516-5",
language = "English (US)",
volume = "50",
pages = "114--123",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis

AU - Yang, Fan

AU - Wang, Qixia

AU - Wang, Zhaoyue

AU - Miao, Qi

AU - Xiao, Xiao

AU - Tang, Ruqi

AU - Chen, Xiaoyu

AU - Bian, Zhaolian

AU - Zhang, Haiyan

AU - Yang, Yue

AU - Sheng, Li

AU - Fang, Jingyuan

AU - Qiu, Dekai

AU - Krawitt, Edward L.

AU - Gershwin, M. Eric

AU - Ma, Xiong

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Although a variant of primary biliary cirrhosis (PBC) characterized by features of autoimmune hepatitis (AIH) has been recognized for many years, few studies with ample numbers of patients have focused on its natural history. This study aimed to clarify the natural history, prognosis, and response to therapy in a cohort of patients with PBC with AIH features. We retrospectively analyzed 277 PBC patients without AIH features and 46 PBC patients with AIH features seen between September 2004 and April 2014. The 5-year adverse outcome-free survival of PBC patients with AIH features was 58 % compared to 81 % in PBC patients without AIH features. Multivariate analysis in the patients with AIH features indicated that total bilirubin ≥2.70× the upper limit of normal predicted a poor prognosis (p = 0.008, relative risk 8.39, 95% confidence interval (CI) 1.73, 40.73). Combination therapy with ursodeoxycholic acid (UDCA) and immunosuppression provided better short-term responses in PBC patients with AIH features, defined by multiple criteria. Higher aspartate aminotransferase (AST) level at accession suggested better prognosis for PBC patients with AIH features while worse prognosis for PBC patients without AIH features. PBC patients with AIH features differ from those without AIH features in terms of natural history, prognostic indicators, and response to therapy.

AB - Although a variant of primary biliary cirrhosis (PBC) characterized by features of autoimmune hepatitis (AIH) has been recognized for many years, few studies with ample numbers of patients have focused on its natural history. This study aimed to clarify the natural history, prognosis, and response to therapy in a cohort of patients with PBC with AIH features. We retrospectively analyzed 277 PBC patients without AIH features and 46 PBC patients with AIH features seen between September 2004 and April 2014. The 5-year adverse outcome-free survival of PBC patients with AIH features was 58 % compared to 81 % in PBC patients without AIH features. Multivariate analysis in the patients with AIH features indicated that total bilirubin ≥2.70× the upper limit of normal predicted a poor prognosis (p = 0.008, relative risk 8.39, 95% confidence interval (CI) 1.73, 40.73). Combination therapy with ursodeoxycholic acid (UDCA) and immunosuppression provided better short-term responses in PBC patients with AIH features, defined by multiple criteria. Higher aspartate aminotransferase (AST) level at accession suggested better prognosis for PBC patients with AIH features while worse prognosis for PBC patients without AIH features. PBC patients with AIH features differ from those without AIH features in terms of natural history, prognostic indicators, and response to therapy.

KW - Autoantibodies

KW - Autoimmune hepatitis

KW - Autoimmunity

KW - Cholestasis

KW - Overlap syndrome

KW - Primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=84957431606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957431606&partnerID=8YFLogxK

U2 - 10.1007/s12016-015-8516-5

DO - 10.1007/s12016-015-8516-5

M3 - Article

C2 - 26411425

AN - SCOPUS:84957431606

VL - 50

SP - 114

EP - 123

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 1

ER -